breakthrough! The new anticancer drug can 'kill' a variety of cancers

The development of human medicine is changing with each passing day. Is there any achievement that deeply surprised you?

Humanity has been battling cancer for years, taking more and more of the initiative in every little bit of medical progress. Now, more and more anticancer drugs are on the market, bringing hope to cancer patients. In 2018, the anticancer drug Vitrakvi was launched in the United States, which attracted the attention of countries around the world.

Vitrakvi has a dual identity, it is both the first officially approved oral TRK inhibitor and the first " broad-spectrum anticancer drug " independent of tumor type.

" Even anti-cancer drugs have a broad spectrum ? " Many people will ask this question when they hear this news.

As one of the major diseases threatening human health and life, cancer has always been the shadow of many people's hearts. But if there is a special drug that can control cancer, making cancer like chronic diseases such as high blood pressure and diabetes can be considered a blessing in misfortune.

Therefore, it is not difficult to understand that the medical community is so excited about the availability of broad-spectrum anticancer drugs.

1. New anticancer drugs are approved

In June of this year, the good news came again. The Center for Drug Evaluation (CDE) of the State Drug Administration of China issued an announcement granting two breakthrough therapy designations to Ribotinib .

Rebotinib , English name Repotrectinib, code name TPX-0005, is a new generation of oral targeted drugs targeting multiple targets of ALK, ROS1 and NTRK . According to the published trial data, Ribotinib has performed well and has great potential.

In May of this year, the U.S. FDA granted Ribotinib Breakthrough Therapy designation. At present, Ribotinib has obtained seven FDA special approval channel certifications.

2. The domestic test results are released, and the effect is gratifying

Why is Ribotinib so well-recognized? Where is it so great?

At last year's World Lung Cancer Conference, Ribotinib made a stunning appearance and caused a sensation. The data show that in the phase I/II study of TRIDENT-1, the objective response rate of Ribotinib for ROS1-positive patients with specific mutations reached 93% , which refreshed the previous record and was highly expected by the medical community.

In addition, at the 53rd International Society of Pediatric Oncology (SIOP), Harvard Medical School announced the Phase 1/2 clinical data of Ribotinib. The results showed that Ribotinib was well tolerated in pediatric cancer patients. Three of the four tyrosine kinase inhibitor (TKI)-naïve patients had a definite response, and one patient's tumor lesions completely disappeared and a complete remission was achieved .

Recently, the results of the domestic trial of Ribotinib were also announced. Data Display:

In the treatment-naïve group, the overall response rate of 11 Chinese patients reached 91%;

In the second-line group, the overall response rate of 11 Chinese patients was 36%;

In the back-line group, the overall response rate of 4 Chinese patients was 50%;

In the targeted drug resistance group, the overall response rate of 3 Chinese patients was 67%;

The preliminary efficacy analysis of rebotinib is very encouraging and may play an even greater role in the future.

3. Outstanding advantages, clinical trials will continue

At present, the domestic clinical trials of rebotinib are still in progress and recruiting, mainly targeting non-small cell lung cancer solid tumors with rearrangements of ROS1, NTRK1, NTRK2 and NTRK3.

What are the specific advantages of rebotinib, which is expected to be a best-in-class drug candidate for patients with ROS1-positive advanced NSCLC?

First , rebotinib is a specially designed low-molecular-weight macrocyclic TKI with “broad spectrum” that can be used to treat lung, colon, melanoma, thyroid, gastrointestinal, ROS1, TRKA-C and ALK target-positive tract stromal tumor, cholangiocarcinoma and other solid tumors.

Second , clinical data show that compared with other drugs with the same target, Ribotinib has better anti-cancer performance.

More importantly , rebotinib can overcome the currently known resistance problems of ALK, ROS1 and NTRK. Although the current targeted drugs can significantly prolong the survival of patients, resistance problems inevitably arise, and there is no good solution, and rebotinib can fill the corresponding vacancy.

Fourth, taking targeted drugs, these 3 things should be paid attention to

Targeted drugs bring hope to patients, but patients should pay attention to the following points when taking drugs, so as not to affect the treatment effect.

1. Do not increase or decrease the dose by yourself

Do not increase or decrease the dose without authorization. The frequency and dosage of targeted drugs are scientifically formulated. Only by taking the drugs on time and according to the amount can achieve the best effect, reduce adverse reactions, and delay the emergence of drug resistance.

2. Review in time if the effect declines

Pay close attention to your physical condition while taking the medicine, because after a period of time, the tumor may become less sensitive to the medicine and less effective. In this case, it is necessary to review it in time, choose other targeted drugs under the guidance of a doctor, or change the treatment method.

3. Keep an eye out for side effects

Targeted drugs are not a panacea, and side effects such as rash, diarrhea, elevated transaminases, oral mucositis, and oral ulcers may occur. If the symptoms are mild, they can be addressed in a targeted manner. But be careful, if the symptoms are more severe, stop the drug immediately and seek medical attention.

In fact, it is already a fortune to be able to take targeted drugs. After all, not everyone has suitable targets. Therefore, patients must listen to the doctor's advice when taking medicine, and do not be willful, so as not to hurt themselves.

References:

[1] China National Medical Products Administration Center for Drug Evaluation. Information disclosure. Breakthrough treatment announcement. 2022-06-01

[2] The remission rate of patients with drug-resistant mutations is 59%! Ribotinib Receives Two Breakthrough Therapy Designations for Non-Small Cell Lung Cancer in China. Gene Medicines.2022-06-20

[3] 10 things you have to know about taking targeted drugs! Once explained, rash, diarrhea, elevated transaminase.... China Medical Tribune Tumor Today. 2022-03-10

Reproduction is prohibited without the author's permission